Search

Poly (butylene adipate-co-terephthalate) (PBAT) has attracted much attention as a biodegradable polymer, but its biodegradation speed is slow. Starch was blended with PBAT to develop daily packing film with high biodegradation speed, and deep eutectic solvent (DES) composed of choline chloride (CHCl)/glycerol (Gly) (molar ratio of 1:2) was used as a novel plasticizer. The hydrophilic starch is in favor of the breeding of microorganisms, at the same time DES can provide energy for the breeding. The degradation was traced in a simulated composting test using kitchen waste. After the PBAT/starch-DES film was buried in a mixture of food residue for 90 D, the relative weight molecular weight (M w) of the PBAT decreased by about 50%. Furthermore, with the help of DES, the compatibility between PBAT and starch was improved, the PBAT/starch-DES film became more transparent than the PBAT and PBAT/starch film, and its tensile strength reached 7.9 MPa with an elongation at break of 335.6%. This work provided a simple and efficient solution to obtain rapidly degradable films. [Display omitted] • Deep eutectic solvent was used as a novel plasticizer to prepare PBAT/starch film. • The M w reduction of PBAT/starch-DES film was about 50% after 90D. • Kitchen waste was used to study the biodegradation of PBAT composites. • The tensile strength of the PBAT/starch-DES film reached 7.9 MPa. • The elongation at break of the above film was 335.6%. [ABSTRACT FROM AUTHOR]

Abstract To study the association between TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 and Myelodysplastic syndromes (MDS), a total of 90 MDS patients and 143 healthy volunteers were included. The clinical data, bone marrow samples of patients and peripheral blood samples of volunteers were obtained. We found TET2 rs2454206 G/A genotype, TET2 rs12498609 G/C genotype and ASXL1 rs3746609 A/G genotype in 13.3%, 11.1%, 10.1% MDS patients and in 42.7%, 22.4%, 23.8% healthy volunteers (P < 0.001; P = 0.029; P = 0.009, respectively). TET2 rs2454206 G/A genotype was associated with higher serum LDH level in MDS (P = 0.025). Patients with TET2 rs12498609 G/C genotype were characterized with higher frequency of mutated SRSF2 gene (P = 0.042) and lower occurrence rate of anemia (P = 0.026) than those with C/C genotype. ASXL1 rs3746609 A/G genotype linked with higher thrombocyte counts (P = 0.02) and percent of total T lymphocyte (P = 0.029), whereas with lower percent of NK cell (P = 0.032) and B lymphocyte (P = 0.007). None of these three SNPs had impact on the overall survival and disease progression to AML. We concluded that People with TET rs2454206 G/A genotype, TET2 rs12498609 G/C genotype or ASXL1 rs3746609 A/G genotype were related to lower prevalence of MDS. All of the three SNPs were associated with certain laboratory features in MDS patients. [ABSTRACT FROM AUTHOR]